Sudeep Pharma IPO Day 1 Highlights: Issue subscribed 1.42x, GMP signals strong listing - Should you apply?

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma IPO was subscribed 1.42x by 5:00 pm on day 1. The retail portion was booked at 1.51x, and NII portion was subscribed 3.00x. Meanwhile, Qualified Institutional Buyers (QIBs) portion had only received 9% bids till now.

The company has received bids for 1,50,15,075 shares against 1,05,64,927 shares on offer.

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma IPO GMP today is ₹111. Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Sudeep Pharma share price was indicated at ₹704 apiece, which is 18.72% higher than the IPO price of ₹593.

Grey market premium indicates investors' readiness to pay more than the issue price.

Sudeep Pharma IPO Day 1 LIVE: The brokerage said, "At the upper price band of ₹593, SPL is available at a P/E of 48x (FY25 diluted basis), which appears to be fairly priced. The company is well-positioned for sustained long-term growth, supported by robust operational performance, the NSS acquisition that strengthens its European foot-print in infant nutrition and formulations, and its planned foray into the high-growth battery-grade minerals segment. Coupled with a strong balance sheet, dedicated R&D focus, and continued product innovation, SPL presents a compelling long-term story. We therefore assign a SUBSCRIBE rating for investors with a medium- to long-term investment horizon."

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma Key Risks

High Customer Concentration: Nearly 42% of the company’s revenue comes from its top ten customers. Losing even one major client could significantly impact overall earnings.

Cash Flow Pressure: The company’s receivable cycle has stretched to around 135 days, which can strain liquidity and limit availability of cash for routine operations.

Raw Material Dependency: About 65% of raw materials are sourced from the top ten suppliers. Any disruption in this supply chain could affect production or increase input costs.

Geographic Concentration: A large share of Sudeep Pharma’s manufacturing and R&D facilities are located in Gujarat. Localised disruptions—such as policy changes, natural disasters or regional issues—could affect business continuity.

Export-Related Risks: With more than half of revenue coming from international markets, the company remains exposed to regulatory changes, tax revisions and geopolitical tensions that may impact export demand or increase costs.

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma Key Strengths

Strong Profit Growth: The company’s bottom line has expanded at a much faster pace than revenue, with profit growing nearly 50% annually from FY23 to FY25. This highlights strong demand for its specialty ingredients and efficient operations.

High-Quality, Globally Approved Products: Sudeep Pharma holds major international certifications, including USFDA approval, ensuring its products meet stringent global quality standards. This strengthens its credibility and supports wider market access.

High Customer Retention: Around 83% of its recent revenue comes from repeat customers, reflecting strong client trust and consistent product performance.

Healthy Profit Margins: The company maintains robust profitability, with margins exceeding 27%. In simple terms, for every ₹100 it earns, Sudeep Pharma retains about ₹27 as profit, demonstrating strong operational efficiency.

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma IPO GMP today is ₹111. Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Sudeep Pharma share price was indicated at ₹704 apiece, which is 18.72% higher than the IPO price of ₹593.

Grey market premium indicates investors' readiness to pay more than the issue price.

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma IPO was fully subscribed, 1.06x by 3:05 pm day 1. The retail portion was also completely booked at 1.19x, and NII portion was subscribed 2.07x. Meanwhile, Qualified Institutional Buyers (QIBs) portion had only received 9% bids till now.

The company has received bids for 1,12,33,250 shares against 1,05,64,927 shares on offer.

Sudeep Pharma IPO Day 1 LIVE: Anand Rathi Research advised investors to subscribe to the IPO with a long-term view, while noting that the issue appeared fully priced. At the upper end of the price band, the company was valued at 48.3x its FY25 estimated earnings, implying a post-issue market capitalisation of ₹6,697.9 crore.

The brokerage underlined Sudeep Pharma’s expansion strategy, including the creation of its wholly owned subsidiary SAMPL to build on its mineral chemistry capabilities for advanced materials. This includes a new PCAM facility that will manufacture battery-grade iron phosphate for LFP batteries used in electric vehicles and energy storage systems. Analysts also highlighted the company’s plans to scale its presence in regulated markets such as the US and Europe by using USFDA-approved facilities, expanding exports and moving closer to customers through local warehousing and on-ground sales teams.

Considering these growth drivers and expansion initiatives, Anand Rathi maintained that the IPO remained fully priced and assigned a Subscribe – Long Term recommendation.

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma raised ₹268.5 crore from anchor investors on Thursday, November 20, by allotting 45,27,823 shares at ₹593 each, according to a circular on the BSE website. The anchor book drew interest from a wide range of major domestic institutions, including SBI Mutual Fund, HDFC MF, ICICI Prudential MF, Nippon India MF, WhiteOak Capital MF, Aditya Birla Sun Life MF, Motilal Oswal MF, Quant MF, Bandhan MF, UTI MF and Edelweiss MF, along with insurers Tata AIA Life Insurance and SBI Life Insurance.

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma IPO was subscribed 81% by 1:20 pm day 1. The retail portion was booked 91%, and NII portion was subscribed 1.54x. Meanwhile, Qualified Institutional Buyers (QIBs) portion had received 8% bids till now.

The company has received bids for 85,35,550 shares against 1,05,64,927 shares on offer.

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma IPO GMP today is ₹111. Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Sudeep Pharma share price was indicated at ₹704 apiece, which is 18.72% higher than the IPO price of ₹593.

Grey market premium indicates investors' readiness to pay more than the issue price.

Sudeep Pharma IPO Day 1 LIVE: Master Trust has also assigned a 'subscribe' tag to the public issue, saying, "India’s food and nutritional ingredients market, valued at $22 billion in 2024, is expanding rapidly on the back of rising health awareness, urbanisation, and a growing middle-income population. The sector is expected to grow at a CAGR of 8.1% to reach $32 billion by 2029. Sudeep Pharma Ltd is strategically positioned to capitalise on this rapid expansion across the Pharmaceutical, Food, Nutrition and Speciality ingredients markets. With a technology-driven manufacturing ecosystem, in-house process capabilities, and a diversified portfolio of over 100 products, the company is well-aligned with the sector’s evolving needs. Investors may consider the IPO as a potential long-term investment opportunity."

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma IPO was subscribed 50% by 11:55 am day 1. The retail portion was booked 66%, and NII portion was subscribed 82%. Meanwhile, Qualified Institutional Buyers (QIBs) portion had not received any bids till now.

The company has received bids for 53,30,325 shares against 1,05,64,927 shares on offer.

Sudeep Pharma IPO Day 1 LIVE: Advising investors to apply to the public issue for the long-term, Swastika Investmart report says, "The company delivered a strong performance with rising revenues, high BITDA margins, and an impressive FY25 RONW of 27.88%. It operates as a preferred partner for critical pharma-grade ingredients, serving a solid roster of marquee global customers. The issue is considered "aggressively priced" at a P/E of 45–48x, fully capturing its current stable profitability. This steep valuation leaves very little room for immediate listing gains or short-term "pops." Aggressive investors are advised to apply only if they have a holding horizon of 2–5 years."

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma IPO was subscribed 35% by 11:10 am day 1. The retail portion was booked 45%, and NII portion was subscribed 55%. Meanwhile, Qualified Institutional Buyers (QIBs) portion had not received any bids till now.

The company has received bids for 37,14,800 shares against 1,05,64,927 shares on offer.

Sudeep Pharma IPO Day 1 LIVE: As much as 50 per cent of the net issue is reserved for qualified institutional buyers (QIBs), and 35 per cent of the net issue is reserved for retail investors. The remaining 15 per cent is reserved for non-institutional investors (NIIs).

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma IPO GMP today is ₹122. Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Sudeep Pharma share price was indicated at ₹715 apiece, which is 20.57% higher than the IPO price of ₹593.

Grey market premium indicates investors' readiness to pay more than the issue price.

Sudeep Pharma IPO Day 1 LIVE: Sudeep Pharma is a manufacturer of excipients and speciality ingredients for the pharmaceutical, food and nutrition industries. It has a domestic and global presence in key regions such as the US, South America, Europe, the Middle East, Africa, and Asia-Pacific.

Sudeep Pharma IPO Day 1 LIVE: The company's profit and revenue have seen a sustained growth over the last few financial years.

For FY23, the company's profit stood at ₹62.32 crore, which rose to ₹133.19 crore in FY24 and to ₹138.69 crore in FY25. For the first three months in FY26, the company's profit was ₹30.81 crore.

Its revenue from operations in FY23 was ₹428.74 crore, while in FY24 and in FY25 it was ₹459.28 crore and ₹502 crore, respectively. For the three months ended 30 June 2025, its revenue was ₹124.92 crore.

Sudeep Pharma IPO Day 1 LIVE: The company intends to utilise the net proceeds from the issue for capital expenditure towards the procurement of machinery for its production line located at Nandesari Facility I. Besides, some parts of the net proceeds will be used for general corporate purposes.

Sudeep Pharma IPO Day 1 LIVE: As the IPO is closing on Tuesday, November 25, the allotment of shares is expected to be finalised on the next business day, Wednesday, November 26. Successful bidders can get the shares on Thursday, November 27, and those who fail to get the allotment will get the refund on the same day. Sudeep Pharma IPO will list on the BSE and the NSE on Friday, November 28.